pharmaceuticals

pharmaceuticals Articles

Proteostasis Therapeutics expects to price less than 4 million shares in the range of $12 to $14 apiece in an initial public offering valued up to around $62 million.
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Corvus Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Reata Pharmaceuticals has amended filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Merrill Lynch has decided to add Pfizer as its new top pick for 2016. The firm reiterated a Buy rating with a $39 price target.
Regeneron Pharmaceuticals reported disappointing fourth-quarter financial results before the markets opened on Tuesday.
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political purposes, you may want to start buying.
After Pfizer and Merck released their most recent earnings reports last week, analysts weighed in on both of these pharmaceutical giants.
Over the past week, Alere and a few biotech other companies made absolutely massive runs, either up and down.
Mapi Pharma expects to price more than 3 million shares in the range of $15 to $17 in an initial public offering valued up to about $61 million.
Therapure Biopharma has announced that, due to current conditions in capital markets, it would postpone its initial public offering.
Sinovac Biotech Ltd. (NASDAQ: SVA) was riding high early Thursday morning, following the offer for a potential buyout, but it looks like this company doesn’t want to take the bait. It announced...
Merck reported mixed fourth-quarter financial results before the markets opened Wednesday.
In its IPO, Beigene plans to offering more than 5 million American depositary shares in an expected price range of $22 to $24 apiece.
Pfizer reported better-than-expected fourth-quarter and full-year 2015 results before markets opened Tuesday morning.